Abstracts tagged "outcomes and rheumatoid arthritis (RA)"

Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 496 • 2016 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Ee Tzun Koh¹, Angela Marie Chan¹, Wei Qiang See², Wenwei Xiang², Khai Pang Leong¹ and Tan Tock Seng Rheumatoid Arthritis Study Group, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine…
Abstract Number: 1520 • 2016 ACR/ARHP Annual Meeting
RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year
Susan M. Goodman¹, Susan J. Bartlett², Ryan Cummings³, Kathleen Andersen³, Edward F. DiCarlo⁴, Mark P. Figgie⁵, Laura T. Donlin⁶, Dana E. Orange⁷ and Vivian P. Bykerk⁸, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁵Orthopaedics, Hospital for Special Surgery, New York, NY, ⁶Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Post-op flares are frequent for RA patients after total hip (THA) and total knee arthroplasty (TKA), when medications are discontinued to mitigate infection…
Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld^2,3, Eunice Chang⁴, Elya Papoyan⁴ and Michael S. Broder⁴, ¹Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…
Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 2671 • 2015 ACR/ARHP Annual Meeting
Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis
Abhijeet Danve¹, Harlan Sayles², Ted R. Mikuls³ and James R. O'Dell², ¹Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate (MTX) is routinely used as the first-line drug for rheumatoid arthritis (RA). About 1 in 3 RA patients achieve excellent RA control with…
Abstract Number: 2590 • 2015 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Brian Coburn¹, Geoffrey M. Thiele¹, Michael J. Duryee², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, WH Robinson⁶, Alan Erickson⁷, Mary Brophy⁸, James R. O'Dell¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁸VA Boston Heathcare System, Boston, MA
Background/Purpose: Anti-citrullinated protein antibody (ACPA) positivity is associated with more rapid radiographic progression in rheumatoid arthritis (RA). A majority of prior studies, however, have assessed…
Abstract Number: 1577 • 2015 ACR/ARHP Annual Meeting
Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Melanie Rohr¹, James R. O'Dell¹, Abhijeet Danve², Harlan Sayles¹, Geoffrey M. Thiele³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) outcomes have improved substantially due to the development of new drug therapies, but also due to emphasis on early aggressive MTX…
Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
Abstract Number: 575 • 2015 ACR/ARHP Annual Meeting
Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi¹, Shuji Asai², Toki Takemoto², Nobuyuki Asai³, Tatsuo Watanabe², Naoki Ishiguro⁴ and TBCR Study Group, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: : Currently, there is no clarity regarding which biologic to switch to when patients fail to respond to TNF inhibitors (TNFis). Detailed information for…
Abstract Number: 469 • 2015 ACR/ARHP Annual Meeting
Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
Virginia Pascual-Ramos¹ and Irazú Contreras-Yáñez², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The window of opportunity concept states that there are superior clinical responses and the potential for remission, when patients with rheumatoid arthritis (RA) are…
Abstract Number: 467 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
In Je Kim¹, Hyesook Park², Sang-Cheol Bae³ and Jisoo Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ²Dep of Preventive medicine, Ewha Womans University School of medicine, Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Internal Medicine, Ewha Womans Univeristy School of Medicine, Seoul, South Korea
Background/Purpose: Despite high clinical disease activity measured by joint counts and global assessments, some patients with active rheumatoid arthritis (RA) have normal acute-phase reactant (APR)…
Abstract Number: 2401 • 2014 ACR/ARHP Annual Meeting
Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy?
Liam O'Neil¹, Carol A. Hitchon², David B. Robinson³, Navjot Dhindsa¹, Hani El-Gabalawy³ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Severe disease and poor outcomes have been described in First Nation (FN) patients with Rheumatoid Arthritis (RA). We examined the contributions of interrupted and…
Abstract Number: 2390 • 2014 ACR/ARHP Annual Meeting
Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Chandana Keshavamurthy¹, Kevin Kuriakose², Deepak Chandra², Aneet Kaur², Horace Spencer² and Nasim A. Khan³, ¹Division of Rheumatology, University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy is recommended to improve rheumatoid arthritis (RA) outcomes. The aim of this study was to determine…
Abstract Number: 1060 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study
H Cawston¹, F Bourhis¹, T Le² and E Alemao³, ¹OptumInsight, Nanterre, France, ²Bristol-Myers Squibb, Hopewell, NJ, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Musculoskeletal surgeries and procedures substantially improve the quality of life of patients with RA, but represent an important burden in terms of medical costs.…